VYVGART powers strong growth and expanding labels
- Q2 2026 product net sales reached $1.5 billion, up 60% year over year.
- U.S. sales drove the majority of Q2 revenue at $1.3 billion.
- VYVGART is now the first and only treatment approved across all gMG serotypes.
- The Phase III ADAPT OCULUS study for ocular MG was positive, paving the way for an sBLA filing.
- The FDA concluded its CIDP worsening review with a favorable label update.
A rare disease winner with momentum
argenx has moved from a promising biotech to a highly profitable drug company. VYVGART and VYVGART Hytrulo continue to exceed expectations, producing $1.5 billion of product net sales in Q2 2026 alone. The recent approval of VYVGART for seronegative gMG makes it the only treatment approved across all serotypes, offering a major near-term growth catalyst.
The bull case rests on VYVGART adding patient groups while maintaining pricing power. The company wants 10 labeled indications by 2030. The positive Phase III ADAPT OCULUS study in ocular MG could add about 7,000 addressable patients. Open questions focus on whether the upcoming myositis data will achieve statistical significance to support a broad label expansion into rheumatology.
The bear case revolves around execution risks. CIDP growth may slow down after the easiest switch patients move from IVIg to VYVGART. U.S. gross-to-net adjustments remain stable for now, but investors still need to watch whether the shift to self-injection under the pharmacy benefit will pressure margins over time.
High-priced drugs for narrow diseases
argenx sells biologic medicines for rare autoimmune diseases. These drugs are complex antibody medicines, not simple pills. The main product is efgartigimod, sold as VYVGART for IV use and VYVGART Hytrulo for under-the-skin use.
Most revenue comes from treating generalized myasthenia gravis, or gMG, and chronic inflammatory demyelinating polyneuropathy, or CIDP. Both are serious immune-driven nerve or muscle diseases. The value pitch is simple. If VYVGART can reduce harmful antibodies and improve daily function, payers may accept a high price because the patient groups are small and the need is high.
The prefilled syringe matters because it lets more patients self-administer. This grows volume but shifts more U.S. reimbursement from Medicare Part B medical coverage to Part D pharmacy coverage. This shift raised gross-to-net discounts in 2025. Management noted that U.S. net pricing and gross-to-net adjustments remain stable, easing the margin worry for now.
One engine with several shots
VYVGART and VYVGART Hytrulo in gMG
This is the core franchise. The recent U.S. approval expanded use to all adult gMG patients, including triple seronegative patients.
VYVGART Hytrulo in CIDP
CIDP is a major launch. The key question is whether growth continues strongly after early patients switch from IVIg.
VYVGART in ocular MG
The Phase III ADAPT OCULUS study was positive. argenx plans an sBLA filing, and the company estimates about 7,000 added addressable patients.
Efgartigimod in other autoimmune diseases
Phase II proof-of-concept data were positive in myositis and Sjogren's. The company is advancing efgartigimod into Phase III for Graves' disease.
Empasiprubart
This is a second pipeline antibody in registrational studies for MMN and CIDP. The MMN readout expected in Q4 2026 is a major pipeline test.
ARGX-119
ARGX-119 is in a registrational study in congenital myasthenic syndrome, or CMS. It gives argenx another chance outside the VYVGART franchise.
U.S. drives the revenue
This mix uses Q2 2026 product net sales by region: $1.3 billion in the U.S., $136 million in rest of world, $102 million in Japan (including a $25 million one-off benefit), and $5 million from product supply to Zai Lab in China. The company is highly concentrated in VYVGART.
What could break the story
CIDP growth stalls after switch patients
High impact · Medium oddsThe early CIDP launch benefited from patients switching from IVIg. That pool may not repeat forever. If new patient starts slow down, the market may question how large the CIDP opportunity really is.
Gross-to-net discounts pressure margins
Medium impact · Medium oddsSelf-injection moved more U.S. use into pharmacy benefit channels. That raised gross-to-net discounts earlier in 2025. While currently stable, a renewed rise would pressure profit even if prescriptions grow.
Pipeline readouts disappoint
High impact · Medium oddsargenx wants 10 labeled indications by 2030. That plan depends on repeated clinical wins. Empasiprubart in MMN, upcoming myositis data, and newer indications like Graves' disease all carry trial risk.
Biosimilars arrive after exclusivity
High impact · Low oddsVYVGART has a long runway, but not a permanent one. The base regulatory exclusivity period is expected to run until December 2033 in the U.S. and August 2032 in the EU. As those dates get closer, copycat biologic risk becomes more important.
In one breath
What does argenx sell?
argenx sells VYVGART and VYVGART Hytrulo, versions of efgartigimod. They are antibody medicines used for rare immune nerve and muscle diseases such as gMG and CIDP.
Why is VYVGART important to ARGX stock?
VYVGART is the main revenue engine. It generated $1.5 billion of product net sales in Q2 2026 alone and drives the company's profitability.
What changed with the seronegative gMG approval?
The FDA expanded VYVGART and VYVGART Hytrulo to all adult gMG patients in the U.S. That includes triple seronegative patients who previously had no approved treatment option.
What is the biggest risk for argenx now?
The main near-term risk is whether CIDP keeps growing after early switch patients. A second risk is whether U.S. discounts stay stable as more patients use the self-injection format.
